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cPure white cell aplasia (PWCA) is an infrequent,
cquired, single-line autoimmune myelopathy [1]
haracterized by the absence of not only circulating
eutrophils but also, more speciﬁcally, their precur-
ors in the bone marrow (BM). The deﬁning term
as ﬁrst used in 1983 [2] in analogy to the more
requent and better known pure red cell aplasia,
ith the understanding that not all “white cells” are
ffected, but rather only the neutrophil series.
WCA is recognized as an autoimmune myelopathy
1], even if the demonstration of an immune attack
y antibodies and/or T lymphocytes may be uncer-
ain. PWCA may present as idiopathic but may also
e associated with thymomas. It has been treated
ore or less satisfactorily with a variety of immu-
omodulating agents, including corticosteroids, cy-
losporin, high-dose immunoglobulins, and
hymectomy when associated with thymoma. We
eport the ﬁrst case, to our knowledge, of a patient
ith PWCA who proved refractory to all other
reatments but was successfully treated with alloge-
eic BM transplantation followed by 9 consecutive
onor lymphocyte infusions (DLIs).
The patient (UPN 1436) was a North Italian
ale and 56 years old at the time of this writing
April 2006). No occupational hazards, drug-con-
uming habits, or thymomas were present. Severe
acterial infections were recurring, including mas-
oiditis with cranial nerve VII palsy. Severe neutro-
enia (0.2  109/L neutrophils) was detected in
998. No granulocytic precursors were found in the
M aspirates. He was treated with 3 courses of
ntilymphocytic globulin (ALG), alternating horse
nd rabbit products, cyclosporin A (CyA) and gran-
locyte colony-stimulating factor. Neutrophil re-
onstitution was obtained for 2 years after horse
LG administration, for 6 months after rabbit ALG
dministration, and for another 4 months after re-
eated horse ALG administrations. However, severe
eutropenic relapses occurred jointly with severe bacte-
ial infections. In September 2002, he received an allo-
eneic BM transplant (absolute neutrophil count, 6.9 
08/kg) from his HLA-identical 53-year-old sister after a ieduced intensity conditioning regimen (thiotepa 10mg/
g, cyclophosphamide [CY] 100 mg/kg). At transplanta-
ion, neutrophils amounted to 0.4  109/L; the few
xtant neutrophils were morphologically normal,
nd large granular lymphocytes were absent on
mears. The immunophenotype of peripheral lym-
hocytes was CD3 (88%), CD8 (73.4%), CD4
6.7%), CD19 (3.4%), CD16 (7%), CD56
2.8%), CD57. The BM aspirate showed normal
rythroid and megakaryocytic lineages, lymphoid
20%) and plasmacytic (10%) cells, eosinophils at
arious stage of maturation, but a total absence of
eutrophil precursors. BM biopsy conﬁrmed these
ndings; total cellularity was estimated at 25%. Cy-
ogenetic examination showed a normal XY karyo-
ype. Seven BM cultures performed during this period
howed 24 granulocyte-macrophage colony-forming
nits (7-59 in our laboratory) and 20 burst-forming
nits, erythroid (BFU-Es) (7-33). No inhibition of
ranulocyte-macrophage colony-forming units could
e clearly demonstrated in the presence of the pa-
ient’s serum.
The post-transplantation course was uneventful,
ith graft-versus-host disease (GVHD) prophylaxis
omposed of methotrexate-cyclosporin A (MTX-
yA). Time to 500 neutrophils and 50  109/L
latelets was 20 days. Full donor chimerism was
ttained on day 20, but from then on a mixed
himerism supervened, with a nadir of donor pre-
ursors of 23% on day 42, concomitant with se-
ere neutropenia. A program of escalating DLI was
mplemented, with a starting dose of 1  105/kg and
n ending dose of 1  107/kg. Nine DLIs were
erformed in 2 separate blocks (Figure 1) and fol-
owed by increasing donor chimerism, as evaluated
y cytogenetics and short tandem repeat polymerase
hain reaction analysis of T and BM cells. Full
onor chimerism was reached on day 740, with
omplete reconstitution of BM granulocytopoiesis.
o GVHD was registered, and infectious compli-
ations did not recur.
As in many other cases of PWCA, no serologic
nhibition of neutrophilic granulocytopoiesis could
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Letter to the Editor988e demonstrated in this patient. However, the pres-
nce of eosinophilic precursors in the BM pretrans-
lantation aspirate indicated that the antineutrophil
recursor effect started downstream of the division
etween the eosinophilic and neutrophilic lines.
ull donor chimerism in BM and blood could be
btained only after 9 gradually incremental DLIs
nd coincided with complete remission of granulo-
ytopoiesis in the BM aspirates and of mature neu-
rophils in the blood. Mixed chimerism after non-
yeloablative allotransplantations has been found
o be effective in autoimmune diabetes of nonobese
iabetic mice, with reversal of insulitis despite the
resence of recipient T cells [4]. A similar experi-
nce was reported in some clinical cases of rheuma-
oid arthritis [5] and psoriatic arthritis [6], but in
thers full chimerism was necessary [7, 8].
A clinically recognizable graft-versus-autoim-
unity effect was found in patients with coinciden-
al diseases after having developed GVHD [9]. In
ther cases, however, relapses despite full donor
himerism have been reported [10]. A possible in-
erpretation of this last occurrence may be consis-
ent with the concept of long-lived recipient plas-
acytes residing in postulated survival niches [11].
owever, in this case of persistent, refractory, and
elapsing PWCA, attainment of full donor chimer-
sm after 9 consecutive DLIs coincided with com-
igure 1. Post-transplantation course of absolute neutrophil count
STR) technology. Shaded area indicates normal absolute neutrophlete remission of the disease.EFERENCES
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